Unichem Laboratories · NSE: UNICHEMLAB · BSE: 506690
Q1 FY22 results · Apr–Jun 2021
Unichem Laboratories reported revenue from operations of ₹297.91 crore (down 6.1% from Q1 FY21) and net loss of ₹11.49 crore for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 297.91 | 317.27 | −6.1% | 274.12 | +8.7% |
| Other income | 15.79 | 16.71 | −5.5% | 7.83 | +101.6% |
| Total income | 313.70 | 333.98 | −6.1% | 281.95 | +11.3% |
| Profit before share of associates & JVs and tax | (8.97) | 7.00 | Turned loss | 3.20 | Turned loss |
| Share of profit/(loss) of associates & JVs | (0.08) | 0.04 | (0.24) | ||
| Net profit for the period | (11.49) | 2.43 | Turned loss | (0.41) | Loss widened |
| EPS, basic (₹) | (1.63) | 0.35 | Turned loss | (0.06) | Loss widened |
| Net margin (%) | -3.9 | 0.8 | -0.1 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 200.80 | 240.77 | −16.6% | 261.09 | −23.1% |
| Other income | 12.54 | 18.73 | −33.0% | 4.91 | +155.6% |
| Total income | 213.34 | 259.50 | −17.8% | 265.99 | −19.8% |
| Profit before tax | (36.38) | (7.55) | Loss widened | 12.43 | Turned loss |
| Net profit for the period | (27.83) | (7.55) | Loss widened | 0.86 | Turned loss |
| EPS, basic (₹) | (3.95) | (1.07) | Loss widened | 0.12 | Turned loss |
| Net margin (%) | -13.9 | -3.1 | 0.3 |
Consolidated
- Filed with BSE
- 31 Jul 2021, 15:09 IST
- Board meeting
- 31 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2021, 15:09 IST
- Board meeting
- 31 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE